| Brain | Glioma | RTOG 0834: Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed GlioblastomaMultiforme: A Phase II Study. | Trial Details |
| Brain | Other | CCCWFU 91105: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients. | Trial Details |
| Breast | Adjuvant | NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy. | Trial Details |
| Breast | Adjuvant | NSABP B-B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative Her2-Low Invasive Breast Cancer | Trial Details |
| Breast | Adjuvant | SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and Her-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. | Trial Details |
| Breast | Neoadjuvant | ACOSOG Z1071: A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-T4, N1-N2, M0) at Initial Diagnosis. | Trial Details |
| Breast | Neoadjuvant | CALGB 40603: Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/Her2-Negative Resectable Breast Cancer. | Trial Details |
| Breast | Recurrent / Advanced / Metastatic | CTSU / NCCTG N0733: Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane. | Trial Details |
| Cancer Control | | CCCWFU 97609: Impact of Genomics and Exposures on Disparities in Breast Cancer Radio- sensitivity. | Trial Details |
| Cancer Control | | SCUSF Pilot 2011-1: Treatment of Painful Moist Desquamation in Women Undergoing Whole Breast Radiation Therapy Following Breast Conserving Surgery. | Trial Details |
| Cancer Control | Prevention | CALGB 70604:A Randomized Phase III Study of Standard Dosing using Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer. | Trial Details |
| Cancer Control | Prevention | SWOG S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting on Zoledronic Acid Treatment. | Trial Details |
| Colorectal | Advanced/Metastatic | CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. | Trial Details |
| Colorectal | Cancer Control | NCCTG N08CB A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity. | Trial Details |
| Colorectal | Colon | CALGB 80702: A Phase III trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. | Trial Details |
| Colorectal | Colon | NCCTG N0949: Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer | Trial Details |
| Genitourinary | Cancer Control/ Prevention | CALGB 70604:A Randomized Phase III Study of Standard Dosing using Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer. | Trial Details |
| Genitourinary | Prostate | RTOG 0831: A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer [Prevention of Erectile Dysfunction Study (PEDS)]. | Trial Details |
| Genitourinary | Urothelium | CALGB 90601:A RANDOMIZED DOUBLE-BLINDED PHASE III STUDY COMPARING GEMCITABINE, CISPLATIN, AND BEVACIZUMAB TO GEMCITABINE, CISPLATIN, AND PLACEBO IN PATIENTS WITH ADVANCED TRANSITIONAL CELL CARCINOMA | Trial Details |
| Gynecologic | Cervical | GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy. | Trial Details |
| Gynecologic | Cervix | GOG 0240: A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab vs. the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix. | Trial Details |
| Gynecologic | Cervix | GOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy. | Trial Details |
| Gynecologic | Endometrial | GOG 0086P: A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus and Ixabepione, Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer. | Trial Details |
| Gynecologic | Endometrial | GOG 0224: Randomized Phase II Evaluation of Continuous Prosgestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of a Typical Endometrial Hyperplasia (AEH) OR EIN Patients That Desire Preservation. | Trial Details |
| Gynecologic | Endometrial | GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine Corpus. | Trial Details |
| Gynecologic | Endometrial | GOG 0249: A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma. | Trial Details |
| Gynecologic | Endometrial | GOG 0258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma. | Trial Details |
| Gynecologic | Gestational Trophoblastic Neoplasia | GOG 0242: A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia. | Trial Details |
| Gynecologic | Miscellaneous | ChemoFX: Registry Study - An Observational, Longitudinal, Multi-Center Study Examining Outcomes Associated with the Use of the ChemoFx Assay in Solid Tumor Malignancies. | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | BI 1199.15: Multicenter, randomized, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with Carboplatin and Paclitaxel compared to placebo plus Carbopatin and Paclitaxel in patients with advanced ovarian cancer. | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | EC-FV-06: A Randomized Double-Blind Phase III Trial Comparing ED145 and Pegylated Liposomal Doxorubicin (PLD/DOXIL/CAELYX) in combination versus PLD in Participants with Platinum-Resistant Ovarian Cancer. – Open March 1 | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | GOG 0187: Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy. | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | GOG 0212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103_(IND#70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve A Complete Clinical Response to Primary Platinum/Taxane Chemotherapy. | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | GOG 0213: A Phase III, Randomized, Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer. NCI-SUPPLIED AGENTS: BEVACIZUMAB. | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | GOG 0214: Phase II Double Blind Randomized Trial Evaluation the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer. | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | GOG 0252: Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma. | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | GOG 0262: Randomized Phase III Trial of Every-3-Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | MORAB-003-003PR: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (Farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer. | Trial Details |
| Gynecologic | Ovarian, Primary Peritoneal, Fallopian Tube | MORAB-003-004: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the efficacy and Safety of Weekly Farletuzumab (MORAB-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive Ovarian Cancer in First Relapse. | Trial Details |
| Gynecologic | Tissue Collection | GOG 0136: Acquisition of Human Gynecologic Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention, and Treatment of Cancer. | Trial Details |
| Gynecologic | Uterine | GOG 0250: A RANDOMIZED PHASE III EVALUATION OF DOCETAXEL AND GEMCITABINE PLUS G-CSF WITH BEVACIZUMAB, VERSUS DOCETAXEL AND GEMCITABINE PLUS G-CSF WITH PLACEBO IN THE TREATMENT OF RECURRENT OR ADVANCED LEIOMYOSARCOMA OF THE UTERUS. NCI SUPPLIED AGENT: BEVACIZUMAB. | Trial Details |
| Gynecologic | Uterine | GOG 0261: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (MMT) of the Uterus. | Trial Details |
| Head and Neck | Metastatic | ECOG E1305: A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer. | Trial Details |
| Head and Neck | Squamous Cell | RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer. | Trial Details |
| Lung | NCSLC | ACOSOG Z4099/RTOG 1021: A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) | Trial Details |
| Lung | NCSLC | CALGB 30607: Randomized, Phase II, Double-Blinded Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer. | Trial Details |
| Lung | NCSLC | CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition In COX-2 Expressing Advanced Non-Small Cell Lung Cancer (Pending Consent form changes for IRB approval). | Trial Details |
| Lung | NCSLC | ECOG 1505:A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB – IIIA NSCLC. | Trial Details |
| Lung | NCSLC | RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located NSCLC in Medically Inoperable Patients. | Trial Details |
| Lung | NCSLC | SWOG S0424: Molecular Epidemiology Case- Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men (closed to smokers). | Trial Details |
| Lung | NCSLC | SWOG S0819 - Phase III Intergroup A Randomized, Phase III Study Comparing Carboplatin/PaclitaxelorCarboplatin/Paclitaxel/Bevacizumabwith or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). | Trial Details |
| Lung | Small Cell | CALGB 30504: Combination Cisplatin, Etoposide, and Sunitinib Maleate for Untreated Extensive Stage Small Cell Lung Cancer. | Trial Details |
| Lung | Small Cell | CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide. | Trial Details |
| Lung | Small Cell | SWOG S0802: A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) (Pending consent form changes for IRB approval). | Trial Details |
| UGI | Esophagus | RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma. | Trial Details |
| UGI | Liver | CALGB 80802: A Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC). | Trial Details |
| UGI | Pancreas | ACOSOG Z5041 : A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma. | Trial Details |
| UGI | Pancreas | RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. | Trial Details |
| UGI | Stomach | SWOG S1005: A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer. | Trial Details |